Arkadios Wealth Advisors Decreases Stock Holdings in ICON Public Limited (NASDAQ:ICLR)

Arkadios Wealth Advisors lowered its stake in shares of ICON Public Limited (NASDAQ:ICLR) by 10.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,162 shares of the medical research company’s stock after selling 131 shares during the quarter. Arkadios Wealth Advisors’ holdings in ICON Public were worth $244,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Foyston Gordon & Payne Inc purchased a new stake in shares of ICON Public during the 3rd quarter valued at $11,672,000. Icon Wealth Advisors LLC raised its stake in ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after buying an additional 11,840 shares during the last quarter. Sara Bay Financial acquired a new stake in ICON Public in the third quarter worth about $1,143,000. Whittier Trust Co. grew its stake in shares of ICON Public by 12.3% during the third quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock worth $1,155,000 after acquiring an additional 441 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ICLR. William Blair reiterated an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Barclays cut their target price on ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Citigroup lowered their price target on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, Redburn Atlantic started coverage on ICON Public in a report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price objective on the stock. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, ICON Public currently has a consensus rating of “Moderate Buy” and an average price target of $287.00.

ICON Public Trading Down 0.2 %

ICON Public stock opened at $202.68 on Friday. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The stock’s 50 day simple moving average is $209.32 and its two-hundred day simple moving average is $264.99. ICON Public Limited has a 12 month low of $183.38 and a 12 month high of $347.72. The firm has a market cap of $16.72 billion, a PE ratio of 22.60, a P/E/G ratio of 1.54 and a beta of 1.20.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same period in the previous year, the firm posted $3.10 EPS. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. Analysts anticipate that ICON Public Limited will post 13.44 earnings per share for the current year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.